Infusional 5-FU: Historical evolution, rationale, and clinical experience

ONCOLOGY

Volumn 12, Issue 10 SUPPL. 7, 1998, Pages 19-22

  Lokich, Jacob ^a  

^a Cancer Center of Boston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; SPARFOSIC ACID; UFT;

BOLUS INJECTION; CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DIGESTIVE SYSTEM CANCER; DRUG MECHANISM; DRUG RESPONSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; STOMATITIS;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS, PHASE III; FLUOROURACIL; HISTORY, 20TH CENTURY; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS;

EID: 0031788356     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Heidelberger C, Chaudhuri NK, Danneberg P, et al: Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179(4561):663-666, 1957.
2. Ansfield F, Klotz J, Nealon T, et al: A phase III study comparing the clinical utility of four regimens of 5-fluorouracil: A preliminary report. Cancer 39:34-40, 1977.
3. Moertel CG, Schutt AJ, Reitemeier RJ, et al: A double blind comparison of 5-fluorouracil administered by slow infusion and rapid injection. Cancer Res 32:2717-2719, 1972.
4. Cummings B: Anal cancer-radiation alone or with cytotoxic drugs? Int J Radiat Oncol Biol Phys 27:173-175, 1993.
5. Seifert P, Baker LH, Reed MD, et al: Comparison of continuously infused 5-fluorouracil with bolus injection in patients with colorectal adenocarcinoma. Cancer 36:123-128, 1975.
6. MacMillan WE, Wolberg WH, Welling PG: Pharmacokinetics of 5-fluorouracil in humans. Cancer Res 38:3479-3482, 1978.
7. Drewinko B, Yang LY: Cellular basis for the inefficacy of 5-fluorouracil in human colon carcinoma. Cancer Treat Rep 69:1391-1398, 1985.
8. Lokich JJ, Bothe A, Fine N, et al: Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 48:2565-2568, 1981.
9. Lokich JJ, Moore C: Chemotherapy associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 101:789-800, 1984.
10. Lokich JJ, Bothe A, Yanes L, et al: Continuous infusion chemotherapy with an ambulatory pump. Proceedings, 13th International Congress of Chemotherapy, Vienna, Austria, August, 1983.
11. Belt RJ, Davidner ML, Myron MC, et al: Continuous low dose 5-fluorouracil for adenocarcinoma: Confirmation of activity. Proc Am Soc Clin Oncol 4:349 (abstr), 1985.
12. Lokich JJ, Ahlgren JD, Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma. J Clin Oncol 7:425-432, 1989.
13. Hansen RM, Ryan I, Anderson T, et al: Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 88:668-674, 1996.
14. Rougier PH, Paillot B, Laplanche A, et al: End results of a multicentric randomized trial comparing 5FU in continuous systemic infusion (CI) to bolus administration (B) in measurable metastatic colon cancer (MCC). Proc Am Soc Clin Oncol 11 (abstr), 1992.
15. Weinerman R, Shah A, Fields A, et al: Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. Am J Clin Oncol (CCT) 15(6):518-523, 1992.
16. Lokich J: Infusional 5-fluorouracil for colorectal cancer: Literature review and current status. J Infus Chemo 3(4): 119-124, 1993.
17. Lokich J: Infusional 5-FU for advanced colorectal cancer. J Infus Chemo 5:208-211, 1995.
18. Fryer J: Comparison of survival times: Infusional chemotherapy versus bolus delivery. J Infus Chemother 3:142-144, 1993.
19. Lokich JJ, Ahlgren JD, Cantrell J, et al: A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. Cancer 67:14-19, 1991.
20. Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16(1):301-308, 1998.
21. Leichman CG, Fleming TR, Muggia FM, et al: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 13:1303-1311, 1995.
22. Issacson S: 5-Fluorouracil and folinic acid in the treatment of colorectal carcinoma: A randomized trial of two different schedules of administration. Second International Conference on Gastro-Intestinal Cancer, Jerusalem, Israel, 1989.
23. Lokich J: Improving 5-Fluorouracil: Biomodulation, pharmacomodulation or infusional administration schedules? Cancer Invest 16(4):293-294, 1998.
24. Hryniuk WM, Figueredo A, Goodyear M: Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Sem Oncol 14(4):3-11, 1987.
25. Lokich J, Anderson N: Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration and cost comparisons. Cancer 70:998-1002, 1992.
26. Leichman CG, Leichman L, Spears CP, et al: Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: A phase II study in patients with disseminated colorectal cancer. J Natl Cancer Inst 85(1):41-44, 1993.
27. Pazdur R: New agents for colorectal cancer: Oral fluorinated pyrimidines. In ASCO Educational Book, pp 300-315, 1998.
28. Punt CJA: New drugs in treatment of colorectal carcinoma. Cancer 83(4):679-689, 1998.